Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies.

Cell Biol Toxicol · 2026 · PMC12982217 · PMID 41673329

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

A PBPK study showed an increasing trend in t 1/2 , and a decreasing trend in CL z/F when acalabrutinib was co-administered with CYP3A inhibitors (fluconazole, isavuconazole) (Chen et al. 2022 ), as compared to acalabrutinib alone, which was consistent with the trend of our animal results.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.